Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387946 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
NCT00387946 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 630 participants.
The verdict
NCT00387946, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
Study Summary
The primary study objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are to assess the: craving for cigarettes, nicotine withdrawal symptoms, and safety of dianicline.
Interventions
- DRUG SSR591813L (dianicline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387946
The ClinicalTrials.gov registry entry for NCT00387946 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SSR591813L (dianicline) is the first listed.
NCT00387946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387946 about?
NCT00387946 is a clinical study titled "Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)". The primary study objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are to assess the: craving for cigarettes, nicotine withdrawal symptoms, and safety of dianicline.
What is the current status of trial NCT00387946?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2006-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00387946?
The interventions under investigation include: SSR591813L (dianicline) (DRUG).
Who is sponsoring clinical trial NCT00387946?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.